ArticleFrontiers in psychiatry2026
Inflammation-HDL axis indices differentiate drug-naïve first-episode mania and recurrent mania from healthy controls: a covariate-adjusted study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bipolar disorder (BD) is associated with immune dysregulation and cardiometabolic risk, yet low-cost biomarkers reflecting immune-lipid interactions across illness stages are not well defined. Methods: We compared 168 individuals with BD (69 drug-naive first-episode mania; 99 with a history of recurrent mania who were euthymic at assessment) and 60 controls (18-65 years). Diagnoses were established using SCID-5 and manic symptoms were assessed with the Young Mania Rating Scale (YMRS). Morning blood samples were used to compute the systemic inflammation response index (SIRI), neutrophil-to-high-density lipoprotein cholesterol ratio (NHR), monocyte-to-HDL ratio (MHR), low-density lipoprotein to HDL ratio (LHR), and the atherogenic index of plasma (AIP). Group differences were tested with general linear models adjusted for age, sex, and body mass index, applying false discovery rate correction across 12 indices. Results: YMRS was higher in first-episode mania than in euthymic recurrent patients (28.12 ± 3.10 vs 1.08 ± 1.18; p<0.001). After adjustment, SIRI, NHR, and MHR showed robust group effects; both BD groups had higher SIRI and NHR than controls, and MHR was elevated in both patient groups. LHR was higher in first-episode mania, whereas AIP was higher in the recurrent group compared with controls. Conclusion: Inflammation-HDL axis markers (SIRI, NHR, MHR) distinguish BD from controls independent of covariates, supporting immune-metabolic dysregulation and warranting prospective validation for risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.